ICD-10-PCS FY2024 code changes

Historical release · ICD-10-PCS FY2024 · Effective October 1, 2023 – March 31, 2024 ICD-10-PCS FY2027 is the release in force (effective October 1, 2026).

Part of FY2024 coding changes

Every recorded ICD-10-PCS code addition, deletion, description revision, billable-status change and tabular-instruction change for FY2024, effective October 1, 2023.

These changes are based on recorded release data. MedCoder does not generate coding changes with AI.

Release: ICD-10-PCS FY2024
Effective: October 1, 2023
Code set period: 2023-10-01 through 2024-03-31

FY2024 at a glance

78Added78 of them valid for submission 5Deleted5 were valid for submission 14Revised descriptionsSame code, different wording

Explore the complete recorded change list →

Compare a code

Enter any ICD-10-PCS code to see what this release does to it: added, deleted, description revised, billable status changed, new child codes, or no change at all. The answer is a lookup against the recorded changes below — nothing is generated.

Deleted codes — what to report instead

These codes leave the code set on October 1, 2023. Where a successor was determined from the source files it is named below; where none was, that is stated rather than guessed.

No successor was determined for these codes.

FY2023 (April) code	FY2023 (April) description	FY2024 status	Effective
XV508A4	Destruction of Prostate using Robotic Waterjet Ablation, Via Natural or Artificial Opening Endoscopic, New Technology Group 4	Deleted — not valid for submission	October 1, 2023
XW033G4	Introduction of Plazomicin Anti-infective into Peripheral Vein, Percutaneous Approach, New Technology Group 4	Deleted — not valid for submission	October 1, 2023
XW033H4	Introduction of Synthetic Human Angiotensin II into Peripheral Vein, Percutaneous Approach, New Technology Group 4	Deleted — not valid for submission	October 1, 2023
XW043G4	Introduction of Plazomicin Anti-infective into Central Vein, Percutaneous Approach, New Technology Group 4	Deleted — not valid for submission	October 1, 2023
XW043H4	Introduction of Synthetic Human Angiotensin II into Central Vein, Percutaneous Approach, New Technology Group 4	Deleted — not valid for submission	October 1, 2023

Revised descriptions

The code itself is unchanged; its description is not. A reworded title can move which diagnoses belong under it.

XRGA0R7

Fusion of Thoracolumbar Vertebral Joint using Customizable Interbody Fusion Device, Open Approach, New Technology Group 7

→ Fusion of Thoracolumbar Vertebral Joint using Custom-Made Anatomically Designed Interbody Fusion Device, Open Approach, New Technology Group 7

XRGA3R7

Fusion of Thoracolumbar Vertebral Joint using Customizable Interbody Fusion Device, Percutaneous Approach, New Technology Group 7

→ Fusion of Thoracolumbar Vertebral Joint using Custom-Made Anatomically Designed Interbody Fusion Device, Percutaneous Approach, New Technology Group 7

XRGA4R7

Fusion of Thoracolumbar Vertebral Joint using Customizable Interbody Fusion Device, Percutaneous Endoscopic Approach, New Technology Group 7

→ Fusion of Thoracolumbar Vertebral Joint using Custom-Made Anatomically Designed Interbody Fusion Device, Percutaneous Endoscopic Approach, New Technology Group 7

XRGB0R7

Fusion of Lumbar Vertebral Joint using Customizable Interbody Fusion Device, Open Approach, New Technology Group 7

→ Fusion of Lumbar Vertebral Joint using Custom-Made Anatomically Designed Interbody Fusion Device, Open Approach, New Technology Group 7

XRGB3R7

Fusion of Lumbar Vertebral Joint using Customizable Interbody Fusion Device, Percutaneous Approach, New Technology Group 7

→ Fusion of Lumbar Vertebral Joint using Custom-Made Anatomically Designed Interbody Fusion Device, Percutaneous Approach, New Technology Group 7

XRGB4R7

Fusion of Lumbar Vertebral Joint using Customizable Interbody Fusion Device, Percutaneous Endoscopic Approach, New Technology Group 7

→ Fusion of Lumbar Vertebral Joint using Custom-Made Anatomically Designed Interbody Fusion Device, Percutaneous Endoscopic Approach, New Technology Group 7

XRGC0R7

Fusion of 2 or more Lumbar Vertebral Joints using Customizable Interbody Fusion Device, Open Approach, New Technology Group 7

→ Fusion of 2 or more Lumbar Vertebral Joints using Custom-Made Anatomically Designed Interbody Fusion Device, Open Approach, New Technology Group 7

XRGC3R7

Fusion of 2 or more Lumbar Vertebral Joints using Customizable Interbody Fusion Device, Percutaneous Approach, New Technology Group 7

→ Fusion of 2 or more Lumbar Vertebral Joints using Custom-Made Anatomically Designed Interbody Fusion Device, Percutaneous Approach, New Technology Group 7

XRGC4R7

Fusion of 2 or more Lumbar Vertebral Joints using Customizable Interbody Fusion Device, Percutaneous Endoscopic Approach, New Technology Group 7

→ Fusion of 2 or more Lumbar Vertebral Joints using Custom-Made Anatomically Designed Interbody Fusion Device, Percutaneous Endoscopic Approach, New Technology Group 7

XRGD0R7

Fusion of Lumbosacral Joint using Customizable Interbody Fusion Device, Open Approach, New Technology Group 7

→ Fusion of Lumbosacral Joint using Custom-Made Anatomically Designed Interbody Fusion Device, Open Approach, New Technology Group 7

XRGD3R7

Fusion of Lumbosacral Joint using Customizable Interbody Fusion Device, Percutaneous Approach, New Technology Group 7

→ Fusion of Lumbosacral Joint using Custom-Made Anatomically Designed Interbody Fusion Device, Percutaneous Approach, New Technology Group 7

XRGD4R7

Fusion of Lumbosacral Joint using Customizable Interbody Fusion Device, Percutaneous Endoscopic Approach, New Technology Group 7

→ Fusion of Lumbosacral Joint using Custom-Made Anatomically Designed Interbody Fusion Device, Percutaneous Endoscopic Approach, New Technology Group 7

XW00X27

Introduction of Bromelain-enriched Proteolytic Enzyme into Skin, External Approach, New Technology Group 7

→ Introduction of Anacaulase-bcdb into Skin, External Approach, New Technology Group 7

XW01X27

Introduction of Bromelain-enriched Proteolytic Enzyme into Subcutaneous Tissue, External Approach, New Technology Group 7

→ Introduction of Anacaulase-bcdb into Subcutaneous Tissue, External Approach, New Technology Group 7

The full recorded change list

Every recorded change, grouped by what kind of change it is. Each entry shows the code's own description first; tabular instructions and relationship text are labeled separately beneath it.

Added to the code set (78)

02HW3RZ — Insertion of Short-term External Heart Assist System into Thoracic Aorta, Descending, Percutaneous Approach
02PW3RZ — Removal of Short-term External Heart Assist System from Thoracic Aorta, Descending, Percutaneous Approach
02WW3RZ — Revision of Short-term External Heart Assist System in Thoracic Aorta, Descending, Percutaneous Approach
0CSS0ZZ — Reposition Larynx, Open Approach
0CSS7ZZ — Reposition Larynx, Via Natural or Artificial Opening
0CSS8ZZ — Reposition Larynx, Via Natural or Artificial Opening Endoscopic
0DH17JZ — Insertion of Magnetic Lengthening Device into Upper Esophagus, Via Natural or Artificial Opening
0DH27JZ — Insertion of Magnetic Lengthening Device into Middle Esophagus, Via Natural or Artificial Opening
0DH37JZ — Insertion of Magnetic Lengthening Device into Lower Esophagus, Via Natural or Artificial Opening
0WHC0GZ — Insertion of Defibrillator Lead into Mediastinum, Open Approach
0WHC3GZ — Insertion of Defibrillator Lead into Mediastinum, Percutaneous Approach
0WHC4GZ — Insertion of Defibrillator Lead into Mediastinum, Percutaneous Endoscopic Approach
0WPC0GZ — Removal of Defibrillator Lead from Mediastinum, Open Approach
0WPC3GZ — Removal of Defibrillator Lead from Mediastinum, Percutaneous Approach
0WPC4GZ — Removal of Defibrillator Lead from Mediastinum, Percutaneous Endoscopic Approach
0WPCXGZ — Removal of Defibrillator Lead from Mediastinum, External Approach
0WWC0GZ — Revision of Defibrillator Lead in Mediastinum, Open Approach
0WWC3GZ — Revision of Defibrillator Lead in Mediastinum, Percutaneous Approach
0WWC4GZ — Revision of Defibrillator Lead in Mediastinum, Percutaneous Endoscopic Approach
0WWCXGZ — Revision of Defibrillator Lead in Mediastinum, External Approach
5A09B5K — Assistance with Respiratory Ventilation, Less than 8 Consecutive Hours, Intubated Prone Positioning
5A09C5K — Assistance with Respiratory Ventilation, 8-24 Consecutive Hours, Intubated Prone Positioning
5A09D5K — Assistance with Respiratory Ventilation, Greater than 24 Consecutive Hours, Intubated Prone Positioning
8E0U0EN — Fluorescence Guided Procedure of Female Reproductive System using Pafolacianine, Open Approach
8E0U3EN — Fluorescence Guided Procedure of Female Reproductive System using Pafolacianine, Percutaneous Approach
8E0U4EN — Fluorescence Guided Procedure of Female Reproductive System using Pafolacianine, Percutaneous Endoscopic Approach
8E0U7EN — Fluorescence Guided Procedure of Female Reproductive System using Pafolacianine, Via Natural or Artificial Opening
8E0U8EN — Fluorescence Guided Procedure of Female Reproductive System using Pafolacianine, Via Natural or Artificial Opening Endoscopic
8E0W0EN — Fluorescence Guided Procedure of Trunk Region using Pafolacianine, Open Approach
8E0W3EN — Fluorescence Guided Procedure of Trunk Region using Pafolacianine, Percutaneous Approach
8E0W4EN — Fluorescence Guided Procedure of Trunk Region using Pafolacianine, Percutaneous Endoscopic Approach
8E0W7EN — Fluorescence Guided Procedure of Trunk Region using Pafolacianine, Via Natural or Artificial Opening
8E0W8EN — Fluorescence Guided Procedure of Trunk Region using Pafolacianine, Via Natural or Artificial Opening Endoscopic
X051329 — Destruction of Renal Sympathetic Nerve(s) using Ultrasound Ablation, Percutaneous Approach, New Technology Group 9
X2H03R9 — Insertion of Intraluminal Device, Bioprosthetic Valve into Inferior Vena Cava, Percutaneous Approach, New Technology Group 9
X2H13R9 — Insertion of Intraluminal Device, Bioprosthetic Valve into Superior Vena Cava, Percutaneous Approach, New Technology Group 9
X2H20R9 — Insertion of Intraluminal Device, Bioprosthetic Valve into Right Femoral Vein, Open Approach, New Technology Group 9
X2H30R9 — Insertion of Intraluminal Device, Bioprosthetic Valve into Left Femoral Vein, Open Approach, New Technology Group 9
X2H63V9 — Insertion of Dual-Chamber Intracardiac Pacemaker into Right Atrium, Percutaneous Approach, New Technology Group 9
X2HK3V9 — Insertion of Dual-Chamber Intracardiac Pacemaker into Right Ventricle, Percutaneous Approach, New Technology Group 9
X2HL0F9 — Insertion of Conduit to Short-term External Heart Assist System into Right Axillary Artery, Open Approach, New Technology Group 9
X2HM0F9 — Insertion of Conduit to Short-term External Heart Assist System into Left Axillary Artery, Open Approach, New Technology Group 9
X2HX0F9 — Insertion of Conduit to Short-term External Heart Assist System into Thoracic Aorta, Ascending, Open Approach, New Technology Group 9
X2KH3D9 — Bypass Right Femoral Artery using Conduit through Femoral Vein to Superficial Femoral Artery, Percutaneous Approach, New Technology Group 9
X2KH3E9 — Bypass Right Femoral Artery using Conduit through Femoral Vein to Popliteal Artery, Percutaneous Approach, New Technology Group 9
X2KJ3D9 — Bypass Left Femoral Artery using Conduit through Femoral Vein to Superficial Femoral Artery, Percutaneous Approach, New Technology Group 9
X2KJ3E9 — Bypass Left Femoral Artery using Conduit through Femoral Vein to Popliteal Artery, Percutaneous Approach, New Technology Group 9
X2U4079 — Supplement Coronary Artery/Arteries with Vein Graft Extraluminal Support Device(s), Open Approach, New Technology Group 9
X2UQ0P9 — Supplement Right Upper Extremity Vein with Synthetic Substitute, Extraluminal Support Device, Open Approach, New Technology Group 9
X2UR0P9 — Supplement Left Upper Extremity Vein with Synthetic Substitute, Extraluminal Support Device, Open Approach, New Technology Group 9
XNHG0F9 — Insertion of Tibial Extension with Motion Sensors into Right Tibia, Open Approach, New Technology Group 9
XNHH0F9 — Insertion of Tibial Extension with Motion Sensors into Left Tibia, Open Approach, New Technology Group 9
XNR80D9 — Replacement of Skull with Ultrasound Penetrable Synthetic Substitute, Open Approach, New Technology Group 9
XNRL099 — Replacement of Right Tarsal with Talar Prosthesis Synthetic Substitute, Open Approach, New Technology Group 9
XNRM099 — Replacement of Left Tarsal with Talar Prosthesis Synthetic Substitute, Open Approach, New Technology Group 9
XRGJ0B9 — Fusion of Right Ankle Joint using Open-truss Design Internal Fixation Device, Open Approach, New Technology Group 9
XRGK0B9 — Fusion of Left Ankle Joint using Open-truss Design Internal Fixation Device, Open Approach, New Technology Group 9
XRGL0B9 — Fusion of Right Tarsal Joint using Open-truss Design Internal Fixation Device, Open Approach, New Technology Group 9
XRGM0B9 — Fusion of Left Tarsal Joint using Open-truss Design Internal Fixation Device, Open Approach, New Technology Group 9
XW013L9 — Introduction of Elranatamab Antineoplastic into Subcutaneous Tissue, Percutaneous Approach, New Technology Group 9
XW013S9 — Introduction of Epcoritamab Monoclonal Antibody into Subcutaneous Tissue, Percutaneous Approach, New Technology Group 9
XW033K9 — Introduction of Sulbactam-Durlobactam into Peripheral Vein, Percutaneous Approach, New Technology Group 9
XW033P9 — Introduction of Glofitamab Antineoplastic into Peripheral Vein, Percutaneous Approach, New Technology Group 9
XW033Q9 — Introduction of Posoleucel into Peripheral Vein, Percutaneous Approach, New Technology Group 9
XW033R9 — Introduction of Rezafungin into Peripheral Vein, Percutaneous Approach, New Technology Group 9
XW043K9 — Introduction of Sulbactam-Durlobactam into Central Vein, Percutaneous Approach, New Technology Group 9
XW043P9 — Introduction of Glofitamab Antineoplastic into Central Vein, Percutaneous Approach, New Technology Group 9
XW043Q9 — Introduction of Posoleucel into Central Vein, Percutaneous Approach, New Technology Group 9
XW043R9 — Introduction of Rezafungin into Central Vein, Percutaneous Approach, New Technology Group 9
XW053T9 — Introduction of Melphalan Hydrochloride Antineoplastic into Peripheral Artery, Percutaneous Approach, New Technology Group 9
XW0DXJ9 — Introduction of Quizartinib Antineoplastic into Mouth and Pharynx, External Approach, New Technology Group 9
XW0DXN9 — Introduction of SER-109 into Mouth and Pharynx, External Approach, New Technology Group 9
XW133H9 — Transfusion of Lovotibeglogene Autotemcel into Peripheral Vein, Percutaneous Approach, New Technology Group 9
XW143H9 — Transfusion of Lovotibeglogene Autotemcel into Central Vein, Percutaneous Approach, New Technology Group 9
XX20X89 — Monitoring of Brain Electrical Activity, Computer-aided Detection and Notification, New Technology Group 9
XX2F3W9 — Monitoring of Musculoskeletal Muscle Compartment Pressure, Micro-Electro-Mechanical System, Percutaneous Approach, New Technology Group 9
XXE2X19 — Measurement of Cardiac Output, Computer-aided Assessment, New Technology Group 9
XXE5XY9 — Measurement of Infection, Other Positive Blood/Isolated Colonies Bimodal Phenotypic Susceptibility Technology, New Technology Group 9

Removed from the code set (5)

XV508A4 — Destruction of Prostate using Robotic Waterjet Ablation, Via Natural or Artificial Opening Endoscopic, New Technology Group 4
XW033G4 — Introduction of Plazomicin Anti-infective into Peripheral Vein, Percutaneous Approach, New Technology Group 4
XW033H4 — Introduction of Synthetic Human Angiotensin II into Peripheral Vein, Percutaneous Approach, New Technology Group 4
XW043G4 — Introduction of Plazomicin Anti-infective into Central Vein, Percutaneous Approach, New Technology Group 4
XW043H4 — Introduction of Synthetic Human Angiotensin II into Central Vein, Percutaneous Approach, New Technology Group 4

Description revised (14)

XRGA0R7 — Fusion of Thoracolumbar Vertebral Joint using Custom-Made Anatomically Designed Interbody Fusion Device, Open Approach, New Technology Group 7
Fusion of Thoracolumbar Vertebral Joint using Customizable Interbody Fusion Device, Open Approach, New Technology Group 7 → Fusion of Thoracolumbar Vertebral Joint using Custom-Made Anatomically Designed Interbody Fusion Device, Open Approach, New Technology Group 7
XRGA3R7 — Fusion of Thoracolumbar Vertebral Joint using Custom-Made Anatomically Designed Interbody Fusion Device, Percutaneous Approach, New Technology Group 7
Fusion of Thoracolumbar Vertebral Joint using Customizable Interbody Fusion Device, Percutaneous Approach, New Technology Group 7 → Fusion of Thoracolumbar Vertebral Joint using Custom-Made Anatomically Designed Interbody Fusion Device, Percutaneous Approach, New Technology Group 7
XRGA4R7 — Fusion of Thoracolumbar Vertebral Joint using Custom-Made Anatomically Designed Interbody Fusion Device, Percutaneous Endoscopic Approach, New Technology Group 7
Fusion of Thoracolumbar Vertebral Joint using Customizable Interbody Fusion Device, Percutaneous Endoscopic Approach, New Technology Group 7 → Fusion of Thoracolumbar Vertebral Joint using Custom-Made Anatomically Designed Interbody Fusion Device, Percutaneous Endoscopic Approach, New Technology Group 7
XRGB0R7 — Fusion of Lumbar Vertebral Joint using Custom-Made Anatomically Designed Interbody Fusion Device, Open Approach, New Technology Group 7
Fusion of Lumbar Vertebral Joint using Customizable Interbody Fusion Device, Open Approach, New Technology Group 7 → Fusion of Lumbar Vertebral Joint using Custom-Made Anatomically Designed Interbody Fusion Device, Open Approach, New Technology Group 7
XRGB3R7 — Fusion of Lumbar Vertebral Joint using Custom-Made Anatomically Designed Interbody Fusion Device, Percutaneous Approach, New Technology Group 7
Fusion of Lumbar Vertebral Joint using Customizable Interbody Fusion Device, Percutaneous Approach, New Technology Group 7 → Fusion of Lumbar Vertebral Joint using Custom-Made Anatomically Designed Interbody Fusion Device, Percutaneous Approach, New Technology Group 7
XRGB4R7 — Fusion of Lumbar Vertebral Joint using Custom-Made Anatomically Designed Interbody Fusion Device, Percutaneous Endoscopic Approach, New Technology Group 7
Fusion of Lumbar Vertebral Joint using Customizable Interbody Fusion Device, Percutaneous Endoscopic Approach, New Technology Group 7 → Fusion of Lumbar Vertebral Joint using Custom-Made Anatomically Designed Interbody Fusion Device, Percutaneous Endoscopic Approach, New Technology Group 7
XRGC0R7 — Fusion of 2 or more Lumbar Vertebral Joints using Custom-Made Anatomically Designed Interbody Fusion Device, Open Approach, New Technology Group 7
Fusion of 2 or more Lumbar Vertebral Joints using Customizable Interbody Fusion Device, Open Approach, New Technology Group 7 → Fusion of 2 or more Lumbar Vertebral Joints using Custom-Made Anatomically Designed Interbody Fusion Device, Open Approach, New Technology Group 7
XRGC3R7 — Fusion of 2 or more Lumbar Vertebral Joints using Custom-Made Anatomically Designed Interbody Fusion Device, Percutaneous Approach, New Technology Group 7
Fusion of 2 or more Lumbar Vertebral Joints using Customizable Interbody Fusion Device, Percutaneous Approach, New Technology Group 7 → Fusion of 2 or more Lumbar Vertebral Joints using Custom-Made Anatomically Designed Interbody Fusion Device, Percutaneous Approach, New Technology Group 7
XRGC4R7 — Fusion of 2 or more Lumbar Vertebral Joints using Custom-Made Anatomically Designed Interbody Fusion Device, Percutaneous Endoscopic Approach, New Technology Group 7
Fusion of 2 or more Lumbar Vertebral Joints using Customizable Interbody Fusion Device, Percutaneous Endoscopic Approach, New Technology Group 7 → Fusion of 2 or more Lumbar Vertebral Joints using Custom-Made Anatomically Designed Interbody Fusion Device, Percutaneous Endoscopic Approach, New Technology Group 7
XRGD0R7 — Fusion of Lumbosacral Joint using Custom-Made Anatomically Designed Interbody Fusion Device, Open Approach, New Technology Group 7
Fusion of Lumbosacral Joint using Customizable Interbody Fusion Device, Open Approach, New Technology Group 7 → Fusion of Lumbosacral Joint using Custom-Made Anatomically Designed Interbody Fusion Device, Open Approach, New Technology Group 7
XRGD3R7 — Fusion of Lumbosacral Joint using Custom-Made Anatomically Designed Interbody Fusion Device, Percutaneous Approach, New Technology Group 7
Fusion of Lumbosacral Joint using Customizable Interbody Fusion Device, Percutaneous Approach, New Technology Group 7 → Fusion of Lumbosacral Joint using Custom-Made Anatomically Designed Interbody Fusion Device, Percutaneous Approach, New Technology Group 7
XRGD4R7 — Fusion of Lumbosacral Joint using Custom-Made Anatomically Designed Interbody Fusion Device, Percutaneous Endoscopic Approach, New Technology Group 7
Fusion of Lumbosacral Joint using Customizable Interbody Fusion Device, Percutaneous Endoscopic Approach, New Technology Group 7 → Fusion of Lumbosacral Joint using Custom-Made Anatomically Designed Interbody Fusion Device, Percutaneous Endoscopic Approach, New Technology Group 7
XW00X27 — Introduction of Anacaulase-bcdb into Skin, External Approach, New Technology Group 7
Introduction of Bromelain-enriched Proteolytic Enzyme into Skin, External Approach, New Technology Group 7 → Introduction of Anacaulase-bcdb into Skin, External Approach, New Technology Group 7
XW01X27 — Introduction of Anacaulase-bcdb into Subcutaneous Tissue, External Approach, New Technology Group 7
Introduction of Bromelain-enriched Proteolytic Enzyme into Subcutaneous Tissue, External Approach, New Technology Group 7 → Introduction of Anacaulase-bcdb into Subcutaneous Tissue, External Approach, New Technology Group 7

Sources

Official source data

Publisher: Centers for Medicare & Medicaid Services (CMS) and the National Center for Health Statistics (CDC/NCHS)
Release: ICD-10-PCS FY2024
Source file: 2023.zip
File checksum (SHA-256): 58583d319e2227d2c379a675af47206e025a29da2e709be3400216c1ac3ae598
Rebuilt snapshot: CMS replaced the original October 2023 code file with its April 2024 update. The snapshot compared here is that file with its April 1, 2024 addenda reversed.
Data type: Public domain code descriptions and tabular instructions. No licensed content.

MedCoder-derived analysis

Change detection: Every addition, deletion, description revision, billable-status change and tabular-instruction change on this page is computed by diffing the two code-description files above, line by line.
Editorial analysis: The grouping of changes into themes, the successor determinations and the coder-impact notes are written by MedCoder against those files. They are not CMS statements.
Independence: MedCoder is an independent coding reference built on public federal data. It is not affiliated with, endorsed by or certified by CMS, and it is not an official CMS coding tool.

Continue

All releases in the Change Ledger